文献速递流行病学与生物统计临床试验与 GCP

一种用于肿瘤学Ⅰ期剂量探索研究的直接荟萃分析方法

A straightforward meta-analysis approach for oncology phase I dose-finding studies.
PubMed 文献 · Stat Med · 2022-06-05

针对肿瘤学Ⅰ期剂量探索研究,提出一种简单稳健的两阶段方法,利用惩罚逻辑回归和贝叶斯随机效应荟萃分析估计最大耐受剂量,并用标准R包实现,通过蒙特卡洛模拟研究其性质,并以两个肿瘤学实例说明。

要点

  • 提出两阶段法:惩罚逻辑回归结合贝叶斯随机效应荟萃分析估计最大耐受剂量。
  • 方法可用标准R包实现,便于应用。
  • 通过蒙特卡洛模拟评估方法性质,并用两个肿瘤学实例展示。

核心结论

  • 提出一种简单稳健的两阶段方法,用于利用惩罚逻辑回归和贝叶斯随机效应荟萃分析估计最大耐受剂量。

研究设计与样本

  • 方法学文章,提出两阶段估计最大耐受剂量的方法,通过蒙特卡洛模拟研究其性质,并以两个肿瘤学实例说明。

主要发现

  • 方法通过标准R包实现,蒙特卡洛模拟用于研究其性质,两个肿瘤学实例用于说明。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Phase I early-phase clinical studies aim at investigating the safety and the underlying dose-toxicity relationship of a drug or combination. While little may still be known about the compound's properties, it is crucial to consider quantitative information available from any studies that may have been conducted previously on the same drug. A meta-analytic approach has the advantages of being able to properly account for between-study heterogeneity, and it may be readily extended to prediction or shrinkage applications. Here we propose a simple and robust two-stage approach for the estimation of maximum tolerated dose(s) utilizing penalized logistic regression and Bayesian random-effects meta-analysis methodology. Implementation is facilitated using standard R packages. The properties of the proposed methods are investigated in Monte Carlo simulations. The investigations are motivated and illustrated by two examples from oncology.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Röver C, Ursino M, Friede T, et al. A straightforward meta-analysis approach for oncology phase I dose-finding studies. Stat Med. 2022. PMID: 35661205. doi:10.1002/sim.9484

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。